Mustang Bio (MBIO) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on cell and gene therapies for hematologic cancers and solid tumors, primarily through licensing and partnerships with leading research institutions.

• Pipeline centers on CAR T therapies for hematologic malignancies (notably MB-106 for B-cell NHL/CLL) and solid tumors (MB-101 for glioblastoma), with additional programs in oncolytic viruses.

• Recent strategic shift discontinued several CAR T and gene therapy programs to focus resources on lead candidates.

• No product sales to date; company has incurred substantial operating losses and expects continued losses for the foreseeable future.

Financial performance and metrics

• As of March 31, 2024, accumulated deficit was $386.2 million; cash and cash equivalents were $1.3 million.

• Stockholders' equity as of December 31, 2023, was $123,000, below Nasdaq's minimum requirement.

• Net proceeds from a May 2024 public offering were approximately $3.3 million; June 2024 registered direct offering and private placement raised additional capital.

Use of proceeds and capital allocation

• Company will not receive proceeds from the resale of shares by selling stockholders; proceeds from recent offerings are intended for general corporate purposes and working capital.

• Cost reduction measures include an 81% workforce reduction in April 2024 and reliance on third-party service providers for clinical and manufacturing activities.